Voyager Therapeutics Gross Profit 2014-2022 | VYGR
Voyager Therapeutics gross profit from 2014 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Voyager Therapeutics Annual Gross Profit
(Millions of US $) |
| 2021 |
$37 |
| 2020 |
$171 |
| 2019 |
$104 |
| 2018 |
$8 |
| 2017 |
$10 |
| 2016 |
$14 |
| 2015 |
$17 |
| 2014 |
$ |
| 2013 |
$ |
Voyager Therapeutics Quarterly Gross Profit
(Millions of US $) |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$28 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$1 |
| 2021-03-31 |
$7 |
| 2020-12-31 |
$7 |
| 2020-09-30 |
$118 |
| 2020-06-30 |
$29 |
| 2020-03-31 |
$18 |
| 2019-12-31 |
$33 |
| 2019-09-30 |
$20 |
| 2019-06-30 |
$46 |
| 2019-03-31 |
$5 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
$3 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$6 |
| 2017-09-30 |
$1 |
| 2017-06-30 |
$1 |
| 2017-03-31 |
$1 |
| 2016-12-31 |
$2 |
| 2016-09-30 |
$3 |
| 2016-06-30 |
$4 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$5 |
| 2015-09-30 |
$5 |
| 2015-06-30 |
$5 |
| 2015-03-31 |
$3 |
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.227B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
